louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01402310: Bishop Score, Cervical Length and Multiple Proteins in Cervicovaginal Fluid at 40 Weeks to Predict Onset of Labor
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Prolonged Labor
Keywords: Onset of labor
Bishop score
Cervical length
Multiple proteins
Cervicovaginal fluid
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2011-07-26
Enrollment: 220
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Single tertiary hospital

Brief summary: The purpose of this study is to compare Bishop score, sonographic cervical length and multiple proteins in cervicovaginal fluid at 40 weeks gestation to predict time to spontaneous labor and mode of delivery.


Eligibility criteria: Inclusion Criteria:

* Women between 39+6 and 40+1 weeks of gestation
* singleton pregnancy
* viable fetus with vertex presentation
* intact amniotic membranes
* no pregnancy complications
* absence of labor
* no history of previous uterine surgery
* planned vaginal delivery

Primary outcomes:
measure: Onset of labor/delivery ≤10days
timeFrame: Baseline
Secondary outcomes:
measure: Cesarean delivery in labor
timeFrame: Baseline
Other outcomes:
Locations:
city: Seongnam-si
country: Korea, Republic of
facility: Department of Obstetrics and Gynecology Seoul National University Bundang Hospital
state: Gyeonggi-do
Study officials:
affiliation: Seoul National University Bundang Hospital
name: Kyo Hoon Park, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06892210: Comparing Hydrocortisone and Prednisolone for Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)
Official title: Comparing Hydrocortisone and Prednisolone for Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE4
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Lead sponsor: Copenhagen Respiratory Research
Sponsor class: NETWORK
First posted: 2025-03-24
Enrollment: 2000
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: The study is a cluster randomized controlled trial. It consists of two arms, in which patients will be randomized to receive treatment with either Hydrocortisone or Methylprednisolone.
Primary purpose: TREATMENT

Brief summary: The goal of this cluster randomized controlled trial is to determine the optimal treatment for Acute Exacerbation of Chronic Obstructive Pulmonary Disease. The study compares the effects and side effects of hydrocortisone and prednisolone in patients above 40 years old diagnosed with chronic obstructive pulmonary disease with acute exacerbation. The main question is whether there is a difference in readmission for COPD excerbation or all cause mortality within thirty days.

Participants will randomized to receive treatment with either hydrocortisone or prednisolone.


Eligibility criteria: Inclusion Criteria:

* Age ≥40 years
* Chronic obstructive pulmonary disease with acute exacerbation, unspecified: ICDJ44

Exclusion Criteria:

* All diagnoses that would merit treatment with a specific corticosteroid
* Pregnant or breastfeeding women
* Active tuberculosis or invasive fungal infection

Primary outcomes:
measure: Readmission for COPD exacerbation or death from all causes
timeFrame: 30 days
Secondary outcomes:
measure: Days alive and out of hospital
timeFrame: 14 days
measure: Mortality
timeFrame: 90 days
measure: Readmission for COPD exacerbation
timeFrame: 90 days
measure: All-cause infections
timeFrame: 90 days
measure: Need for mechanical ventilation
timeFrame: 30 days
measure: New onset infections
timeFrame: 30 days
measure: Daily amount of insulin administered to the patient by day 7 or discharge from hospital
timeFrame: 7 days
measure: Gastrointestinal bleeding
timeFrame: 30 days
measure: Blood glucose levels
timeFrame: 7 days
Other outcomes:
measure: Procalcitonin (PCT) at baseline
timeFrame: 7 days
measure: C-reactive protein (CRP) at baseline
timeFrame: 7 days
measure: Blood eosinophil count (EOS) at baseline
timeFrame: 7 days
Locations:
Study officials:
affiliation: COP:RESP
name: Jens-Ulrik Stæhr Jensen, MD, PHD
role: STUDY_DIRECTOR
References:
Clinical trial NCT02430610: Irreversible Electroporation(IRE) For Uterine Cervical Neoplasms
Official title: Irreversible Electroporation(IRE) For Unresectable Uterine Cervical Neoplasms: Phase I and Phase II Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Uterine Cervical Neoplasms
Keywords: irreversible electroporation
Unresectable Uterine Cervical Neoplasms
Lead sponsor: Fuda Cancer Hospital, Guangzhou
Sponsor class: OTHER
First posted: 2015-04-30
Enrollment: 30
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for unresectable Uterine Cervical Neoplasms.

Detailed description: By enrolling patients with unresectable Uterine Cervical Neoplasms adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of percutaneous IRE for unresectable Uterine Cervical Neoplasms.

Eligibility criteria: Inclusion Criteria:

* Uterine Cervical Neoplasms diagnosed by positive biopsy or non-invasive criteria,
* Not suitable for surgical resection,
* Eastern Cooperative Oncology Group (ECOG) score of 0-1,
* A prothrombin time ratio \> 50%,
* Platelet count \> 80x10\^9/L,
* Ability of patient to stop anticoagulant and anti-platelet therapy for seven days prior to and seven days post NanoKnife procedure,
* Able to comprehend and willing to sign the written informed consent form (ICF),
* Have a life expectancy of at least 3 months.

Exclusion Criteria:

* Cardiac insufficiency, ongoing coronary artery disease or arrhythmia,
* Any active implanted device (eg Pacemaker),
* Women who are pregnant or women of child-bearing potential who are not using an acceptable method of contraception,
* Have received treatment with an investigational agent/ procedure within 30 days prior to treatment with the NanoKnife™ LEDC System,
* Are in the opinion of the Investigator unable to comply with the visit schedule and protocol evaluations.

Primary outcomes:
measure: Number of participants with Adverse events
timeFrame: 6 month
Secondary outcomes:
measure: Voltage (A minimum and maximum range of voltage for safe and effective IRE)
timeFrame: 12 months
measure: A minimum and maximum range of voltage for safe and effective IRE
timeFrame: 3 months
measure: Progress free disease (PFS)
timeFrame: 12 months
measure: Overall survival (OS)
timeFrame: 36 months
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Biological treatment center in Fuda cancer hospital
state: Guangdong
Study officials:
affiliation: Fuda Cancer Hospital
name: Lizhi Niu, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT00207610: Iron Supplementation Among Low-Income Postpartum Women
Official title: Phase 3 Study of the Prevention of Postpartum Anemia by Three Different Strategies
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Anemia
Keywords: Anemia
Postpartum
iron
supplements
Lead sponsor: Centers for Disease Control and Prevention
Sponsor class: FED
First posted: 2005-09-21
Enrollment: 959
Sex: FEMALE
Minimum age (years): 13
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Anemia is common among low-income women after they have given birth. Anemia, or low hemoglobin in the blood cells, is usually caused by not having enough iron. Blood cells usually carry oxygen to other parts of the body. Without enough hemoglobin, the ability of blood cells to carry oxygen is decreased. Memory and work may be impaired. The purpose of this study is to evaluate three methods of giving iron to prevent anemia among low-income women after they have given birth.

Detailed description: Currently the Centers for Disease Control and Prevention recommendations to prevent iron deficiency advocate selective screening and treatment of anemia at about 6 weeks postpartum. However, among some groups, such as low income women, data suggest that anemia and iron deficiency are common. This study aims to evaluate the effectiveness of three stategies to prevent iron deficiency among low income postpartum women in Mississippi.

Comparisons: Clinics will be randomized to one of three strategies: 1)Selective anemia screening and treatment of anemic women, 2)universal anemia screening and treatment of anemic women, or 3)universal iron supplementation of 65 mg a day for three months.

Eligibility criteria: Inclusion Criteria:

* postpartum girls and women, 2-6 weeks after birth
* age 13 years or more
* WIC certified

Exclusion Criteria:

* sickle cell anemia
* Hemoglobin \< 7 g/dL

Primary outcomes:
measure: anemia
timeFrame: 6 months postpartum
Secondary outcomes:
Other outcomes:
Locations:
city: Hattiesburg
country: United States
facility: Center for Community Health, University of Southern Mississippi
state: Mississippi
Study officials:
affiliation: University of Southern Mississippi
name: Amal K Mitra, MD, DrPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02717910: Digital Health Game as an Intervention Supporting Tobacco-related Health Literacy in Early Adolescents
Official title: Digital Health Game as an Intervention Supporting Tobacco-related Health Literacy in Early Adolescents: a Feasibility Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Smoking Prevention
Keywords: Games
Adolescent
Health education
Smoking
Health literacy
Lead sponsor: University of Turku
Sponsor class: OTHER
First posted: 2016-03-24
Enrollment: 151
Sex: ALL
Minimum age (years): 10
Maximum age (years): 13
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This feasibility study evaluates acceptability and preliminary effectiveness of a digital health game as an intervention supporting tobacco-related health literacy in 10- to 13-year-old early adolescents. One third of the study participants will receive the health game, on third a web page with similar content and one third will act as a control group without intervention.


Eligibility criteria: Inclusion Criteria:

* Goes to school at 4th, 5th or 6th grade
* Understands and can communicate either in Finnish, Swedish or English
* Has daily access to either a smart phone or tablet computer during free time

Exclusion Criteria:

* Takes part to specialized education

Primary outcomes:
measure: Change in anti-smoking self-efficacy
timeFrame: At baseline and at 2 weeks
Secondary outcomes:
measure: Change in smoking outcome expectations
timeFrame: At baseline and at 2 weeks
measure: Change in attitudes towards tobacco use questionnaire scores
timeFrame: At baseline and at 2 weeks
measure: Change in tobacco use-related motives questionnaire scores
timeFrame: At baseline and at 2 weeks
measure: Actual use of the intervention
timeFrame: During 2 weeks period
measure: Self-assessed interest towards the intervention
timeFrame: At 2 weeks
Other outcomes:
Locations:
city: Three cities
country: Finland
facility: Primary schools (n=6)
state: Southwest Finland
Study officials:
References:
Clinical trial NCT01481610: Safety Study of Renal Function in Patients With Chronic Kidney Failure Taking Lumiracoxib or Diclofenac for Arthralgia
Official title: Comparison of the Effects on Renal Function of Lumiracoxib and Diclofenac in Patients With Chronic Kidney Failure K/DOQI Stage III at the HCSAE PEMEX
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Kidney Failure, Chronic
Arthralgia
Keywords: Kidney Failure, Chronic
Arthralgia
NSAID
Diclofenac
Lumiracoxib
Safety
Lead sponsor: Hospital Central Sur de Pemex
Sponsor class: OTHER
First posted: 2011-11-29
Enrollment: 28
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether the use of lumiracoxib in this particular population is associated with a decrease in glomerular filtration rate (GFR) compared to diclofenac; and to compare the magnitude of such impairment, if any, associated with use of lumiracoxib and diclofenac.


Eligibility criteria: Inclusion Criteria:

* chronic joint pain, requiring analgesia
* pre-existing chronic kidney injury, stage K/DOQI III (GFR 30 - 59 ml/min)
* in a stable phase of CKD (i.e. not AKI, not hospitalized)
* without contraindications for NSAID therapy
* who have signed an informed consent

Exclusion Criteria:

* having received any NSAID 2 weeks prior to study start
* history of / actual PUD
* patients with ESRD (K/DOQI IV, V or replacement therapy)
* history of hypersensitivity or allergies to any of the treatments
* history of / actual GI bleeding
* with impaired liver function tests
* using ACEI / ARB

Primary outcomes:
measure: Change in GFR
timeFrame: Change in GFR will be measured at start of treatment (baseline) and again at the end of treatment (max. 10 days) for each patient
Secondary outcomes:
measure: Use of rescue medication
timeFrame: Use of rescue medication will be assessed at the end of treatment (ie. 10 days after first dose)
measure: Subjective improvement in pain
timeFrame: Pain will be assessed with VAS at the start of treatment and again at the end of treatment (ie. 10 days after first dose)
Other outcomes:
Locations:
city: Mexico City
country: Mexico
facility: Hospital Central Sur de Alta Especialidad PEMEX
state: DF
Study officials:
affiliation: Petroleos Mexicanos - Servicios de Salud
name: Carlos Molina-Calzada, M.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Petroleos Mexicanos - Servicios de Salud
name: Alejandro Arce-Salinas, M.D.
role: STUDY_DIRECTOR
References:
Clinical trial NCT06447610: Lateral Arm Free Flap: a Useful Flap in the Maxillo-facial Surgeon's Therapeutic Armory, Case Series
Official title: Lateral Arm Free Flap: a Useful Flap in the Maxillo-facial Surgeon's Therapeutic Armory, Case Series
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Reconstructive Surgery
Keywords: Free flaps
Reconstructive surgery
Microvascular surgery
maxillofacial surgery
Lead sponsor: CHUV chirurgie orale et maxillofaciale
Sponsor class: OTHER
First posted: 2024-06-07
Enrollment: 8
Sex: ALL
Minimum age (years): 52
Maximum age (years): 87
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Between 2021 and 2022, 8 patients (1 woman and 7 men) underwent reconstruction with a lateral arm free flap in Lausanne, Switzerland (Table 1). Their ages ranged from 52 to 87 years, with a mean age of 65.25 years. The reconstruction site varied from the exenterated orbita for two patients, internal cheek for two patients, retromolar mandible, palate, mouth floor and frontotemporal each for one patient. Reconstruction was done in all patients for oncologic reason. Six patients received primary reconstruction during the same surgery as the tumorectomy and for two patients' reconstruction was done in a second surgery.

Brief summary: Lateral arm free flap harvesting has been well described, it however remains underused compared to other free flaps such as radial forearm and anterolateral thigh free flap. Due to its easy harvesting, low donor site morbidity, versatility as well as useful possibilities of modifications it should be considered more often as valuable reconstruction option in head and neck defect. With this publication we want to describe the operative technique, illustrate it with postoperative pictures and describe the outcome with 8 of our cases operated at University Hospital In Lausanne, Switzerland.

The aim of this study is to be a useful tool for young surgeons and demonstrate the advantages of this useful flap in head and neck reconstructions.


Eligibility criteria: Inclusion Criteria:

* \> 18 years old
* operated between 01 january 2021 and 12 december 2022
* lateral arm free flap operation for primary or secondary cervicofacial reconstruction
* written informed consent

Exclusion Criteria:

* minor patients
* no written informed consent

Primary outcomes:
measure: Flap complication
timeFrame: 01.01.2021-12.01.2022
Secondary outcomes:
measure: Patient complication
timeFrame: 01.01.2021-12.01.2022
measure: oral food intke
timeFrame: 01.01.2021-12.01.2022
measure: revision of anastomoses
timeFrame: 01.01.2021-12.01.2022
Other outcomes:
Locations:
city: Lausanne
country: Switzerland
facility: CHUV oral and maxillofacial surgery
state: Vaud
Study officials:
affiliation: CHUV; oral and maxillofacial surgery , Lausanne, Switzerland
name: Laurence May, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02528110: Radical Gastrectomy and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Gastric Cancer
Official title: A Phase II Study of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Treatment of Locally Advanced Gastric Cancer During Radical Gastrectomy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Malignant Neoplasm of Stomach
Lead sponsor: Wuhan University
Sponsor class: OTHER
First posted: 2015-08-19
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The efficacy of HIPEC in prevention of local recurrence, distant metastasis or peritoneal metastasis in locally advanced gastric cancer is not definite. The hypothesis of the trial is that radical gastrectomy plus HIPEC is superior to only radical gastrectomy in terms of overall survival.

Detailed description: To determine the efficacy of HIPEC in the treatment of locally advanced gastric cancer, patients are randomized into HIPEC group and control group. In HIPEC group, the patients undergo radical gastrectomy with D2 lymphadenectomy and HIPEC with paclitaxel and 5-Fu. Patients in the control group just undergo radical gastrectomy with D2 lymphadenectomy. Patients in both groups receive 6 cycles of postoperative chemotherapy (SOX or XELOX) and are followed up for 5 years or until death.

The trial is designed as a prospective, randomized, open, multicenter and parallel group study.

Eligibility criteria: Inclusion Criteria:

* Histological proved diagnosis of locally advanced gastric cancer.
* No evidence of distant metastases or peritoneal metastases.
* Preoperative examination (CT/MRI) demonstrated resectable gastric cancer with T3-T4 stage.
* Eligible for radical gastrectomy with D2 lymphadenectomy.
* Have not received cytotoxic chemotherapy or radiotherapy.
* Written informed consent is obtained prior to commencement of trial treatment.

Exclusion Criteria:

* Existence of distant metastasis or peritoneal metastasis during surgery (M1).
* Any previous chemotherapy or radiotherapy
* Active systemic infections
* Inadequate cardiac function, renal function, liver function or bone marrow function at the beginning of the trial.
* Female patients who are pregnant or breast feeding

Primary outcomes:
measure: overall survival
timeFrame: 5 years
Secondary outcomes:
measure: progression-free survival
timeFrame: 5 years
measure: distant metastasis rate
timeFrame: 5 years
measure: peritoneal metastasis rate
timeFrame: 5 years
measure: local recurrence rate
timeFrame: 5 years
measure: complication rate
timeFrame: 5 years
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Zhongnan Hospital of Wuhan University
state: Hubei
Study officials:
References:
Clinical trial NCT03770910: The Effect of GIP(3-30)NH2
Official title: The Effect of GIP(3-30)NH2
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Endocrine - Other
Keywords: GIP
Insulin secretin
Incretin hormone
Lead sponsor: University Hospital, Gentofte, Copenhagen
Sponsor class: OTHER
Collaborators: name: Steno Diabetes Center Copenhagen
name: University of Copenhagen
First posted: 2018-12-10
Enrollment: 8
Sex: MALE
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: Infusion of glucose-dependent insulintropic polypeptide (GIP) receptor antagonist and evaluation of effect of insulin secretion in healthy subjects.

Detailed description: Infusion of glucose-dependent insulintropic polypeptide (GIP) receptor antagonist and evaluation of effect of insulin secretion in healthy subjects.

Six study hyperglycemic clamps (10 mmol/l) pr. participant.

Eligibility criteria: Inclusion Criteria:

* Healthy
* BMI 19-28 kg/m\*m
* Stable body weight

Exclusion Criteria:

* Diabetes
* Anemia
* First-degree relatives with diabetes

Primary outcomes:
measure: Insulin secretion
timeFrame: 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Gentofte
country: Denmark
facility: Clinical Metabolic Physiology
state: Copenhagen
city: Copenhagen
country: Denmark
facility: Clinical Metabolic Physiology
state: Gentofte
Study officials:
References:
Clinical trial NCT04280510: Pathogenic Study of Adult Immune Enteropathies
Official title: Pathogenic Study of Adult Immune Enteropathies
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Celiac Disease
Autoimmune Enteropathy
Inflammatory Bowel Diseases
Keywords: Celiac Disease
Autoimmune enteropathy
Primary immunodeficiency
Intestinal lymphoma
Liver autoimmune diseases
Lead sponsor: Institut National de la Santé Et de la Recherche Médicale, France
Sponsor class: OTHER_GOV
Collaborators: name: Imagine Institute
First posted: 2020-02-21
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients planned to have blood specimens and possible upper and/or lower digestive endoscopy.

Brief summary: The study focuses the mechanisms underlying the loss of intestinal homeostasis in celiac disease, refractory celiac disease and other immune diseases such as monogenic enteropathy, inflammatory bowel diseases or drug induced intestinal diseases. Mechanisms of transformation of lymphocytes leading to onset of lymphomatous complications of immune enteropathies will be investigated. Mechanisms of loss of hepatic lymphocytic homeostasis will also be assessed in liver associated diseases.


Eligibility criteria: Inclusion Criteria:

* 18 years or over
* affiliated to social insurance
* signed informed consent

Exclusion Criteria:

* pregnancy
* under guardianship
* not able to sign informed consent

Primary outcomes:
measure: Intestinal Lymphocytes count
timeFrame: Baseline
measure: DNA sequencing
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Clichy
country: France
facility: Hôpital Beaujon
city: Créteil
country: France
facility: Hôpital Henri Mondor
city: Le Kremlin Bicêtre
country: France
facility: Hôpital Bicêtre
city: Paris
country: France
facility: Hôpital Saint Louis
city: Paris
country: France
facility: Hôpital Saint Antoine
city: Paris
country: France
facility: Hôpital Cochin
Study officials:
affiliation: APHP, Université de Paris (Université Paris Descartes)
name: Georgia MALAMUT, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: